4//SEC Filing
STANKOVICH THOMAS 4
Accession 0001235802-23-000075
CIK 0001427570other
Filed
Jul 5, 8:00 PM ET
Accepted
Jul 6, 4:16 PM ET
Size
10.1 KB
Accession
0001235802-23-000075
Insider Transaction Report
Form 4
STANKOVICH THOMAS
Chief Financial Officer
Transactions
- Sale
Common Stock, $0.001 par value per share
2023-03-31$2.60/sh−109$283→ 5,982 total - Sale
Common Stock, $0.001 par value per share
2023-05-31$2.41/sh−98$236→ 5,788 total - Sale
Common Stock, $0.001 par value per share
2023-04-30$2.36/sh−96$227→ 5,886 total - Purchase
Common Stock, $0.001 par value per share
2023-06-30$1.52/sh+17,702$26,907→ 23,490 total
Footnotes (2)
- [F1]On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.45 to $1.54, inclusive. The reporting person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.
Documents
Issuer
ReShape Lifesciences Inc.
CIK 0001427570
Entity typeother
Related Parties
1- filerCIK 0001181166
Filing Metadata
- Form type
- 4
- Filed
- Jul 5, 8:00 PM ET
- Accepted
- Jul 6, 4:16 PM ET
- Size
- 10.1 KB